The US Food and Drug Administration (FDA) on Friday approved a highly anticipated new drug designed to slow cognitive decline in patients in mild and early stages of Alzheimer's disease.
accelerated process
Leqembi and Aduhelm, which were jointly developed by Japan's Eisai and Biogen of the United States,"represent an important advancement in the ongoing fight to effectively treat Alzheimer's disease," the FDA"Alzheimer's disease immeasurably incapacitates the lives of those who suffer from it and has devastating effects on their loved ones," Billy Dunn of the FDA's Center for Drug Evaluation and Research said in a statement.
Preliminary data from a trial of Leqembi was released in September and found it slowed cognitive decline in Alzheimer's patients by 27 percent.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
FDA approves Biogen, Eisai Alzheimer’s drugAn Alzheimer’s drug from Biogen and Eisai has received accelerated approval from the Food and Drug Administration, the companies and agency announced Friday.
Lire la suite »
FDA approves Alzheimer's drug that modestly slows the diseaseU.S. health officials have approved a closely watched Alzheimer's drug that modestly slows the disease, but could have potential safety risks that patients and doctors will have to carefully weigh.
Lire la suite »
FDA Approves Drug for Early Onset Alzheimer’s DiseaseThe FDA has approved lecanemab for Alzheimer's disease, even though trial results showed modest cognitive benefits and cases of amyloid-related imaging abnormalities
Lire la suite »
U.S. FDA approves Alzheimer's drug that appears to slow rate of cognitive declineThe drug, to be sold under the brand Leqembi, belongs to a class of treatments that aims to slow advance of the neurodegenerative disease by removing sticky clumps of the toxic protein beta amyloid from the brain.
Lire la suite »
FDA approves new antibody to slow Alzheimer’s disease, even as safety concerns lingerThe U.S. Food and Drug Administration has approved a controversial Alzheimer’s disease treatment for broad use—with caveats.
Lire la suite »